ITGAE and neoplasm: In summary, we demonstrated that a DC vaccine generated using the CD103+cDC1 subset and loaded with OS cell lysates as a source of tumor antigens induced tumor regression when injected into the primary tumor and stimulated a systemic immune response resulting in the regression of the untreated tumor on the contralateral side.